Evaluation of dosing strategy for pembrolizumab for oncology indications
Freshwater, Tomoko, Kondic, Anna, Ahamadi, Malidi, Li, Claire H, de Greef, Rik, de Alwis, Dinesh, Stone, Julie A
Published in Journal for immunotherapy of cancer (16.05.2017)
Published in Journal for immunotherapy of cancer (16.05.2017)
Get full text
Journal Article
Population pharmacokinetics and exposure–response of selumetinib and its N‐desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas
Schalkwijk, Stein, Zhou, Li, Cohen‐Rabbie, Sarit, Jain, Lokesh, Freshwater, Tomoko, So, Karen, He, Zhongqing, Gioni, Ioanna, Tomkinson, Helen, Vishwanathan, Karthick, Zhou, Diansong
Published in Cancer chemotherapy and pharmacology (01.08.2021)
Published in Cancer chemotherapy and pharmacology (01.08.2021)
Get full text
Journal Article
Mechanistic Modeling of a Novel Oncolytic Virus, V937, to Describe Viral Kinetic and Dynamic Processes Following Intratumoral and Intravenous Administration
Parra-Guillen, Zinnia P., Freshwater, Tomoko, Cao, Youfang, Mayawala, Kapil, Zalba, Sara, Garrido, Maria J., de Alwis, Dinesh, Troconiz, Iñaki F.
Published in Frontiers in pharmacology (23.07.2021)
Published in Frontiers in pharmacology (23.07.2021)
Get full text
Journal Article
Immunogenicity of pembrolizumab in patients with advanced tumors
van Vugt, Marianne J H, Stone, Julie A, De Greef, Rik H J M M, Snyder, Ellen S, Lipka, Leslie, Turner, David C, Chain, Anne, Lala, Mallika, Li, Mengyao, Robey, Seth H, Kondic, Anna G, De Alwis, Dinesh, Mayawala, Kapil, Jain, Lokesh, Freshwater, Tomoko
Published in Journal for immunotherapy of cancer (08.08.2019)
Published in Journal for immunotherapy of cancer (08.08.2019)
Get full text
Journal Article
Effects of Trimethoprim on the Clearance of Apricitabine, a Deoxycytidine Analog Reverse Transcriptase Inhibitor, and Lamivudine in the Isolated Perfused Rat Kidney
Nakatani-Freshwater, Tomoko, Babayeva, Mariana, Dontabhaktuni, Aruna, Taft, David R
Published in The Journal of pharmacology and experimental therapeutics (01.11.2006)
Published in The Journal of pharmacology and experimental therapeutics (01.11.2006)
Get full text
Journal Article
Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors
Do, Khanh, Wilsker, Deborah, Ji, Jiuping, Zlott, Jennifer, Freshwater, Tomoko, Kinders, Robert J, Collins, Jerry, Chen, Alice P, Doroshow, James H, Kummar, Shivaani
Published in Journal of clinical oncology (20.10.2015)
Published in Journal of clinical oncology (20.10.2015)
Get full text
Journal Article
Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months
Leijen, Suzanne, van Geel, Robin M J M, Sonke, Gabe S, de Jong, Daphne, Rosenberg, Efraim H, Marchetti, Serena, Pluim, Dick, van Werkhoven, Erik, Rose, Shelonitda, Lee, Mark A, Freshwater, Tomoko, Beijnen, Jos H, Schellens, Jan H M
Published in Journal of clinical oncology (20.12.2016)
Published in Journal of clinical oncology (20.12.2016)
Get full text
Journal Article
Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors
Leijen, Suzanne, van Geel, Robin M J M, Pavlick, Anna C, Tibes, Raoul, Rosen, Lee, Razak, Albiruni R Abdul, Lam, Raymond, Demuth, Tim, Rose, Shelonitda, Lee, Mark A, Freshwater, Tomoko, Shumway, Stuart, Liang, Li Wen, Oza, Amit M, Schellens, Jan H M, Shapiro, Geoffrey I
Published in Journal of clinical oncology (20.12.2016)
Published in Journal of clinical oncology (20.12.2016)
Get full text
Journal Article
A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53 -mutant Ovarian Cancer
Oza, Amit M, Estevez-Diz, Maria, Grischke, Eva-Maria, Hall, Marcia, Marmé, Frederik, Provencher, Diane, Uyar, Denise, Weberpals, Johanne I, Wenham, Robert M, Laing, Naomi, Tracy, Michael, Freshwater, Tomoko, Lee, Mark A, Liu, Ji, Qiu, Jingjun, Rose, Shelonitda, Rubin, Eric H, Moore, Kathleen
Published in Clinical cancer research (15.09.2020)
Published in Clinical cancer research (15.09.2020)
Get full text
Journal Article
Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors
Daud, Adil I, Ashworth, Michelle T, Strosberg, Jonathan, Goldman, Jonathan W, Mendelson, David, Springett, Gregory, Venook, Alan P, Loechner, Sabine, Rosen, Lee S, Shanahan, Frances, Parry, David, Shumway, Stuart, Grabowsky, Jennifer A, Freshwater, Tomoko, Sorge, Christopher, Kang, Soonmo Peter, Isaacs, Randi, Munster, Pamela N
Published in Journal of clinical oncology (20.03.2015)
Published in Journal of clinical oncology (20.03.2015)
Get full text
Journal Article
Disentangling Anti‐Tumor Response of Immunotherapy Combinations: A Physiologically Based Framework for V937 Oncolytic Virus and Pembrolizumab
Sancho‐Araiz, Aymara, Parra‐Guillen, Zinnia P., Troconiz, Iñaki F., Freshwater, Tomoko
Published in Clinical pharmacology and therapeutics (01.11.2024)
Published in Clinical pharmacology and therapeutics (01.11.2024)
Get full text
Journal Article
Pivotal Dose of Pembrolizumab: A Dose-Finding Strategy for Immuno-Oncology
Li, Tommy R, Chatterjee, Manash, Lala, Mallika, Abraham, Anson K, Freshwater, Tomoko, Jain, Lokesh, Sinha, Vikram, de Alwis, Dinesh P, Mayawala, Kapil
Published in Clinical pharmacology and therapeutics (01.07.2021)
Published in Clinical pharmacology and therapeutics (01.07.2021)
Get more information
Journal Article
Assessment of Clinical Response to V937 Oncolytic Virus After Intravenous or Intratumoral Administration Using Physiologically-Based Modeling
Parra-Guillen, Zinnia P, Sancho-Araiz, Aymara, Mayawala, Kapil, Zalba, Sara, Garrido, Maria J, de Alwis, Dinesh, Troconiz, Iñaki F, Freshwater, Tomoko
Published in Clinical pharmacology and therapeutics (01.09.2023)
Published in Clinical pharmacology and therapeutics (01.09.2023)
Get more information
Journal Article
Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug‐Drug Interactions and Pediatric Dose Regimens
Cohen‐Rabbie, Sarit, Zhou, Li, Vishwanathan, Karthick, Wild, Martin, Xu, Sherrie, Freshwater, Tomoko, Jain, Lokesh, Schalkwijk, Stein, Tomkinson, Helen, Zhou, Diansong
Published in Journal of clinical pharmacology (01.11.2021)
Published in Journal of clinical pharmacology (01.11.2021)
Get full text
Journal Article
Systematic Literature Review and Meta-Analysis of Response to First-Line Therapies for Advanced/Metastatic Urothelial Cancer Patients Who Are Cisplatin Ineligible
Freshwater, Tomoko, Li, Haojie, Valiathan, Chandni, Li, Mengyao, Perini, Rodolfo, Bracco, Oswaldo L, Frenkl, Tara, Keefe, Stephen
Published in American journal of clinical oncology (01.10.2019)
Published in American journal of clinical oncology (01.10.2019)
Get more information
Journal Article
Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors
Stathis, Anastasios, Tolcher, Anthony W., Wang, Judy S., Renouf, Daniel J., Chen, Lin-Chi, Suttner, Leah H., Freshwater, Tomoko, Webber, Andrea L., Nayak, Tapan, Siu, Lillian L.
Published in Investigational new drugs (01.06.2023)
Published in Investigational new drugs (01.06.2023)
Get full text
Journal Article
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial
Armstrong, Andrew J., Geva, Ravit, Chung, Hyun Cheol, Lemech, Charlotte, Miller Jr, Wilson H., Hansen, Aaron R., Lee, Jong-Seok, Tsai, Frank, Solomon, Benjamin J., Kim, Tae Min, Rolfo, Christian, Giranda, Vincent, Ren, Yixin, Liu, Fang, Kandala, Bhargava, Freshwater, Tomoko, Wang, Judy S.
Published in Investigational new drugs (01.02.2024)
Published in Investigational new drugs (01.02.2024)
Get full text
Journal Article